Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...